ランキング
お知らせ
ログイン
ランキング
お知らせ
ログイン
雑誌詳細
文献概要
今月の特集1 血栓止血学のトピックス—求められる検査の原点と進化
血友病の抗体医薬療法とそのモニタリング
著者： 野上恵嗣1
所属機関： 1奈良県立医科大学小児科
ページ範囲：P.1387 - P.1393
Point
●エミシズマブ（ヘムライブラ®．以下，本剤）は一方の抗原結合部位に活性型第Ⅸ因子，もう一方に第Ⅹ因子を認識するヒト型bispecific抗体であり，活性型第Ⅷ因子機能を代替する製剤である．
●本剤を定期的に皮下投与することによって，インヒビターの有無に関係なく血友病A患者において著明な出血予防効果を示す．
●本剤は通常の活性化部分トロンボプラスチン時間（aPTT）では正確に止血能を評価することはできない．
●本剤の止血モニタリングには種々の包括的凝固機能検査が臨床応用されてきている．
●エミシズマブ（ヘムライブラ®．以下，本剤）は一方の抗原結合部位に活性型第Ⅸ因子，もう一方に第Ⅹ因子を認識するヒト型bispecific抗体であり，活性型第Ⅷ因子機能を代替する製剤である．
●本剤を定期的に皮下投与することによって，インヒビターの有無に関係なく血友病A患者において著明な出血予防効果を示す．
●本剤は通常の活性化部分トロンボプラスチン時間（aPTT）では正確に止血能を評価することはできない．
●本剤の止血モニタリングには種々の包括的凝固機能検査が臨床応用されてきている．
参考文献
1）Manco-Johnson MJ, Abshire TC, Shapiro AD, et al：Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 357：535-544，2007
2）Kitazawa T, Igawa T, Sampei Z, et al：A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 18：1570-1574，2012
3）Shima M, Hanabusa H, Taki M, et al：Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. N Engl J Med 374：2044-2053，2016
4）Shima M, Hanabusa H, Taki M, et al：Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv 1：1891-1899，2017
5）Minami H, Nogami K, Soeda T, et al：The factor VIII heavy chain improves emicizumab-tenase assembly to enhance the factor VIII-mimicking cofactor activity. Thromb Res 166：77-79，2018
6）Shimonishi N, Nogami K, Ogiwara K, et al：Emicizumab improves the stability and structure of fibrin clot derived from factor VIII-deficient plasma, similar to the addition of factor VIII. Haemophilia 26：e97-e105，2020
7）Yada K, Nogami K, Shinozawa K, et al：Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V. Br J Haematol 183：257-266，2018
8）Noguchi-Sasaki M, Soeda T, Ueyama A, et al：Emicizumab, A Bispecific Antibody to Factors IX/IXa and X/Xa, Does Not Interfere with Antithrombin or TFPI Activity In Vitro. TH Open 2：e96-e103，2018
9）Nakajima Y, Nogami K, Yada K, et al：Emicizumab Improves Ex Vivo Clotting Function in Patients with Mild/Moderate Hemophilia A. Thromb Haemost 120：968-976，2020
10）Takeyama M, Nogami K, Matsumoto T, et al：An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A. J Thromb Haemost 18：825-833，2020
11）Minami H, Nogami K, Yada K, et al：Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro. J Thromb Haemost 17：126-137，2019
12）Oldenburg J, Mahlangu JN, Kim B, et al：Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 377：809-818，2017
13）Mahlangu J, Oldenburg J, Paz-Priel I, et al：Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med 379：811-822，2018
14）Pipe SW, Shima M, Lehle M, et al：Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 6：e295-e305，2019
15）Young G, Liesner R, Chang T, et al：A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 134：2127-2138，2019
16）Shima M, Nogami K, Nagami S, et al：A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors. Haemophilia 25：979-987，2019
17）Nogami K, Soeda T, Matsumoto T, et al：Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies. J Thromb Haemost 16：1383-1390，2018
18）Muto A, Yoshihashi K, Takeda M, et al：Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood 124：3165-3171，2014
19）Nogami K, Matsumoto T, Tabuchi Y, et al：Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab. J Thromb Haemost 16：1078-1088，2018
20）Furukawa S, Nogami K, Shimonishi N, et al：Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis-treated haemophilia A patients with inhibitors. Br J Haemato, 2020, in press
21）Yada K, Nogami K, Ogiwara K, et al：Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis. Int J Hematol 110：419-430，2019
掲載雑誌情報
